Hormone receptor negative HER2 positive breast cancer is a specific type of breast cancer where cancer cells produce high levels of the HER2 protein but do not respond to hormones like estrogen and progesterone. Treatment aims to stop cancer growth, improve quality of life, and extend survival by targeting the HER2 protein while managing the disease’s unique characteristics.

Understanding Treatment Goals and Approaches

When someone receives a diagnosis of hormone receptor negative HER2 positive breast cancer, the treatment journey begins with understanding what drives the cancer’s growth. This particular type of cancer accounts for a portion of the 15-20% of all breast cancers that are HER2 positive, meaning the cancer cells produce excessive amounts of a protein called human epidermal growth factor receptor 2 (HER2). However, unlike some other breast cancers, these tumors do not have receptors for estrogen or progesterone on their surface, which means hormones do not fuel their growth.^[2]

The main goal of treatment is to block the signals that tell cancer cells to grow and divide rapidly. Because HER2 drives the aggressive behavior of these tumors, therapies focus on targeting this specific protein. The approach depends on several factors including the stage of the cancer when it’s discovered, whether it has spread to lymph nodes or other parts of the body, the patient’s overall health, and individual preferences about treatment options.^[11]

Treatment planning involves a team of specialists who consider both standard therapies that have been proven effective through years of research and newer approaches being tested in clinical trials. The pathology report plays a crucial role in guiding these decisions. When breast tissue is removed during a biopsy or surgery, it’s sent to a laboratory where specialists examine it under a microscope and perform tests to determine the levels of hormone receptors and HER2. A cancer is considered HER2 positive when special staining shows a score of 3+ on a test called immunohistochemistry (IHC), or when more specialized techniques confirm high levels of HER2.^[18]

Because this cancer type is both hormone receptor negative and HER2 positive, it requires a different treatment strategy than hormone receptor positive HER2 positive cancers. Without hormone receptors, treatments that block estrogen or progesterone won’t be effective. Instead, the entire treatment plan revolves around targeting HER2 and using other therapies that work regardless of hormone status.^[10]

Standard Treatment Options

Standard treatment for hormone receptor negative HER2 positive breast cancer typically involves a combination of surgery, targeted therapy directed at HER2, and chemotherapy. The specific sequence and combination of these treatments depends on the stage of the cancer and other individual factors.

The cornerstone of treatment for HER2 positive cancers is targeted therapy, specifically drugs that block the HER2 protein. The first and most well-known of these is trastuzumab (Herceptin), which has transformed outcomes for patients with HER2 positive breast cancer. Trastuzumab is a type of medicine called a monoclonal antibody that attaches to the HER2 protein on cancer cells and prevents it from sending growth signals. It also helps the immune system recognize and destroy cancer cells. This medication is typically given through an intravenous infusion every three weeks, though some formulations can be given as an injection under the skin.^[18]

Another targeted therapy often used is pertuzumab, which works similarly to trastuzumab but attaches to a different part of the HER2 protein. When pertuzumab and trastuzumab are used together, they can block HER2 more effectively than either drug alone. A combination product called pertuzumab and trastuzumab (Phesgo) allows both drugs to be given together as a single injection under the skin, which can be more convenient than separate intravenous infusions.^[18]

For more advanced situations, other HER2-targeted drugs may be used. Trastuzumab emtansine (Kadcyla) is an antibody-drug conjugate that combines trastuzumab with a chemotherapy medicine. The trastuzumab acts like a delivery vehicle, carrying the chemotherapy directly to HER2 positive cancer cells. This targeted delivery means the chemotherapy is concentrated where it’s needed most, potentially reducing effects on healthy cells. Another antibody-drug conjugate, trastuzumab deruxtecan (Enhertu), works on a similar principle but uses a different chemotherapy agent and can be effective even when other HER2-targeted therapies have stopped working.^[18]

Chemotherapy remains an important part of treatment for hormone receptor negative HER2 positive breast cancer. These are medicines that kill rapidly dividing cells, including cancer cells. Common chemotherapy drugs used include taxanes like paclitaxel and docetaxel, and anthracyclines like doxorubicin and epirubicin. Chemotherapy is often given in cycles, with treatment periods followed by rest periods to allow the body to recover. The specific drugs and schedule depend on whether the cancer is early stage or has spread, and whether treatment is being given before surgery to shrink tumors or after surgery to eliminate any remaining cancer cells.^[12]

Two additional targeted therapies are sometimes used. Neratinib (Nerlynx) is a pill taken daily that blocks signals inside cancer cells that would otherwise cause them to grow. It may be given after a patient has completed a year of trastuzumab to further reduce the risk of cancer returning. Tucatinib (Tukysa) is another pill that blocks HER2 signaling and is often used when cancer has spread to the brain, as it can cross the blood-brain barrier more effectively than some other HER2-targeted drugs.^[18]

Treatment can cause various side effects. Trastuzumab and other HER2-targeted therapies can sometimes affect heart function, so doctors monitor the heart carefully with tests called echocardiograms or similar assessments before and during treatment. Other common side effects include fatigue, diarrhea, and increased risk of infection when white blood cell counts drop. Chemotherapy side effects often include hair loss, nausea, fatigue, and increased vulnerability to infections. Modern supportive care medicines can help manage many of these effects, and the healthcare team works with patients to minimize discomfort and maintain quality of life during treatment.^[12]

Emerging Treatments in Clinical Trials

Research into hormone receptor negative HER2 positive breast cancer continues to advance rapidly, with numerous clinical trials testing new approaches and refining existing treatments. Clinical trials are research studies that test whether new treatments are safe and effective. They occur in phases, each designed to answer specific questions about a new therapy.

Phase I trials focus primarily on safety, testing a new treatment in a small group of people to determine the appropriate dose and identify side effects. Phase II trials expand to more patients to further evaluate safety and begin assessing whether the treatment works against the cancer. Phase III trials involve large groups of patients and compare the new treatment against current standard treatments to determine which approach is more effective.^[11]

One area of active research involves improving antibody-drug conjugates. These medicines combine the targeting ability of antibodies with the cancer-killing power of chemotherapy. Scientists are developing new versions with different chemotherapy agents, exploring whether they might work better or cause fewer side effects than existing options. Some of these investigational antibody-drug conjugates are being tested specifically in patients whose cancer has returned after initial treatment or who didn’t respond well to standard HER2-targeted therapies.^[20]

Researchers are also investigating combinations of HER2-targeted drugs with other types of targeted therapies. For example, some trials are testing whether adding drugs that block specific pathways inside cancer cells, such as the PI3K/AKT/mTOR pathway, can enhance the effectiveness of HER2-targeted treatments. This pathway is involved in cell growth and survival, and blocking it alongside HER2 might prevent cancer cells from finding alternative ways to grow when HER2 is blocked.^[12]

Immunotherapy represents another frontier in treatment research. These treatments harness the body’s own immune system to fight cancer. While immunotherapy has shown remarkable success in some cancer types, its role in HER2 positive breast cancer is still being defined through clinical trials. Some studies are testing checkpoint inhibitors, which remove brakes that prevent immune cells from attacking cancer, in combination with HER2-targeted therapies and chemotherapy. Early results suggest this approach might benefit certain patients, particularly those whose tumors have specific characteristics that make them more likely to respond to immune-based treatments.^[12]

Clinical trials for HER2 positive breast cancer are being conducted at cancer centers throughout the United States, Europe, and other regions around the world. Eligibility for trials depends on numerous factors including the stage of cancer, previous treatments received, overall health status, and specific characteristics of the tumor. Some trials are specifically designed for patients who haven’t received treatment yet, while others focus on those whose cancer has progressed despite standard therapies.

Participation in a clinical trial offers potential benefits including access to new treatments before they become widely available, close monitoring by specialized healthcare teams, and the satisfaction of contributing to medical knowledge that may help future patients. However, clinical trials also involve unknowns about how well new treatments will work and what side effects they might cause. Patients considering trial participation should have detailed discussions with their healthcare team about the potential risks and benefits in their specific situation.^[11]

Researchers are particularly interested in understanding why some HER2 positive cancers stop responding to targeted therapies over time. This phenomenon, called resistance, occurs when cancer cells develop ways to survive despite treatment. Studies are examining the molecular changes that lead to resistance and testing strategies to overcome it. Some trials are evaluating whether giving different combinations of HER2-targeted drugs, or adding other types of targeted therapies, can prevent or reverse resistance.^[20]

Another research focus involves refining treatment for cancer that has spread to the brain, which can occur in HER2 positive breast cancer. The brain is protected by a barrier that prevents many drugs from entering, making treatment challenging. Scientists are testing new HER2-targeted drugs specifically designed to cross this barrier more effectively, as well as evaluating optimal combinations of systemic treatment with radiation therapy directed at brain metastases.^[18]

Most common treatment methods

• Targeted Therapy
  • Trastuzumab (Herceptin) – monoclonal antibody that blocks HER2 protein and helps the immune system destroy cancer cells, typically given for one year in early-stage disease
  • Pertuzumab – blocks a different part of HER2 protein, often combined with trastuzumab for enhanced effectiveness
  • Pertuzumab and trastuzumab (Phesgo) – combination product given as a single injection under the skin
  • Trastuzumab emtansine (Kadcyla) – antibody-drug conjugate that delivers chemotherapy directly to HER2 positive cancer cells
  • Trastuzumab deruxtecan (Enhertu) – antibody-drug conjugate effective even after other HER2-targeted therapies have stopped working
  • Neratinib (Nerlynx) – oral medication that blocks signals inside cancer cells, given after completing trastuzumab
  • Tucatinib (Tukysa) – oral medication that crosses the blood-brain barrier, useful for cancer spread to the brain
• Chemotherapy
  • Taxanes including paclitaxel and docetaxel – drugs that interfere with cancer cell division
  • Anthracyclines including doxorubicin and epirubicin – drugs that damage cancer cell DNA
  • Given in cycles with treatment periods followed by rest periods for body recovery
  • Used in combination with HER2-targeted therapies for enhanced effectiveness
• Surgery
  • Lumpectomy or mastectomy to remove cancerous tissue from the breast
  • Lymph node evaluation to determine cancer spread
  • May be performed after chemotherapy and targeted therapy to shrink tumors first
• Radiation Therapy
  • High-energy beams directed at areas where cancer was located
  • Often given after surgery to eliminate any remaining cancer cells
  • Particularly important for brain metastases in combination with systemic therapy
• Supportive Care
  • Medications to manage nausea, fatigue, and other treatment side effects
  • Regular heart function monitoring during HER2-targeted therapy
  • Blood count monitoring and supportive measures during chemotherapy
  • Nutritional support and counseling to maintain quality of life